Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
- PMID: 11694875
- DOI: 10.1038/ng747
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
Abstract
Inheritance of one defective BRCA2 allele predisposes humans to breast cancer. To establish a mouse model for BRCA2-associated breast cancer, we generated mouse conditional mutants with BRCA2 and/or p53 inactivated in various epithelial tissues, including mammary-gland epithelium. Although no tumors arose in mice carrying conditional Brca2 alleles, mammary and skin tumors developed frequently in females carrying conditional Brca2 and Trp53 alleles. The presence of one wildtype Brca2 allele resulted in a markedly delayed tumor formation; loss of the wildtype Brca2 allele occurred in a subset of these tumors. Our results show that inactivation of BRCA2 and of p53 combine to mediate mammary tumorigenesis, and indicate that disruption of the p53 pathway is pivotal in BRCA2-associated breast cancer.
Similar articles
-
Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.Nat Genet. 1999 May;22(1):37-43. doi: 10.1038/8743. Nat Genet. 1999. PMID: 10319859
-
The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.Oncogene. 2002 Dec 16;21(58):8994-9007. doi: 10.1038/sj.onc.1206177. Oncogene. 2002. PMID: 12483515 Review.
-
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.Nat Genet. 2001 Jul;28(3):266-71. doi: 10.1038/90108. Nat Genet. 2001. PMID: 11431698
-
Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis.Oncogene. 2001 Mar 22;20(12):1445-54. doi: 10.1038/sj.onc.1204222. Oncogene. 2001. PMID: 11313888
-
Insights into aging obtained from p53 mutant mouse models.Ann N Y Acad Sci. 2004 Jun;1019:171-7. doi: 10.1196/annals.1297.027. Ann N Y Acad Sci. 2004. PMID: 15247009 Review.
Cited by
-
Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion.Breast Cancer Res. 2024 Jun 4;26(1):91. doi: 10.1186/s13058-024-01851-4. Breast Cancer Res. 2024. PMID: 38835038 Free PMC article.
-
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.Nat Commun. 2024 May 24;15(1):4430. doi: 10.1038/s41467-024-48715-1. Nat Commun. 2024. PMID: 38789420 Free PMC article.
-
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma.Cancer Cell. 2024 May 13;42(5):904-914.e9. doi: 10.1016/j.ccell.2024.03.008. Epub 2024 Apr 4. Cancer Cell. 2024. PMID: 38579724
-
The CLCF1-CNTFR axis drives an immunosuppressive tumor microenvironment and blockade enhances the effects of established cancer therapies.Res Sq [Preprint]. 2024 Mar 22:rs.3.rs-4046823. doi: 10.21203/rs.3.rs-4046823/v1. Res Sq. 2024. PMID: 38562778 Free PMC article. Preprint.
-
Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability.J Clin Invest. 2024 Apr 1;134(7):e179325. doi: 10.1172/JCI179325. J Clin Invest. 2024. PMID: 38557488 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous